- Details
- Description
-
Packaging Size42c/Bottle
-
Strength75mg
-
CompositonEncorafenib
-
TreatmentMetastatic melanoma & non-small cell lung cancer (NSCLC) with a BRAF V600E or V600K mutation
-
Formcapsule
-
BrandBRATODX
-
Quantity Unit75mg*48c/Bottle
-
ManufacturerBIGBEAR Pharma,Laos PDR
About Encorafenib
Encorafenib is a medication used for the treatment of certain melanoma cancers. It is a small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway. This pathway occurs in many different cancers including melanoma and colorectal cancers.
Melanoma
Indicated in combination with binimetinib for unresectable or metastatic melanoma in patients with a BRAF V600E or V600K mutation, as detected by an FDA-approved test
450 mg PO qDay in combination with binimetinib
Continue until disease progression or unacceptable toxicity
See binimetinib drug monograph for recommended dosing information
Non-Small Cell Lung Cancer
Indicated in combination with binimetinib for unresectable or metastatic non-small cell lung cancer (NSCLC) in patients with a BRAF V600E mutation, as detected by an FDA-approved test
450 mg PO qDay in combination with binimetinib
Continue until disease progression or unacceptable toxicity
See binimetinib drug monograph for recommended dosing information
Metastatic Colorectal Cancer
Indicated in combination with cetuximab for metastatic colorectal cancer (CRC) in patients with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy
300 mg PO qDay in combination with cetuximab
Continue until disease progression or unacceptable toxicity
See cetuximab drug monograph for recommended dosing information
